1. Scrip
  2. >>Business
  3. >>Deals

Tech Transfer Roundup: MD Anderson Working To Unlock Promise Of Tumor-Infiltrating Lymphocytes

 
• By Joseph Haas

The center is partnering with Obsidian to make autologous TILs work better after being infused back into patients by using IL-15, which may be less toxic than the high-dose IL-2 currently used.

Tech Transfer

Tumor-infiltrating lymphocytes have long been regarded as a promising modality for treating solid tumor cancers with cell therapy, but an ongoing challenge in tapping that potential has been manufacturing. Addressing that, along with defining a regulatory path, will be the key barriers to bringing to market a technology that researchers know is effective at fighting solid tumors, University of Texas MD Anderson Cancer Center'sJason Bock told Scrip.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

First Quarter M&A Activity Rose On The Strength Of Three Deals

 
• By Joseph Haas

The biopharma sector made acquisitions with total potential value of $33.6bn during Q1, up substantially from the $9.5bn of Q4 2024, according to data from Evaluate.

China Deal-Making Matures As Foreign Partners Derisk Asset Acquisition

 
• By Xu Hu

Chinese biopharma companies’ alliance strategies are transitioning from immediate cash needs to more strategic management of portfolios, as MNCs continue to hunt for derisked assets.

PureTech Weighs Up Pros And Cons Of Going Private

 
• By Kevin Grogan

The biotech has rejected a takeover bid from Nordic Capital but a sale to private equity could be a solution to the public market's continued reluctance to adequately value PureTech’s hub-and-spoke business model.

GSK Ramps Up Neuroscience Investment With ABL Brain Shuttle Deal

 
• By Andrew McConaghie

The pact could be worth more than $2.6bn and adds to growing big pharma investment in the technology.

More from Business

Trump’s Tariff Rollercoaster Keeps Pharma On Edge

 
• By Jessica Merrill

The rollout of Trump’s tariff plan has been a policy whiplash, but despite a 90-day pause on tariffs, it appears the US president is still holding a grudge with industry over drug pricing.

Trump’s Tariffs Add To European Warning Of $100bn US Exodus

 
• By Andrew McConaghie

European pharma leaders want to see a deal so that no tariffs are imposed on medicines – but they also want the European Union to urgently rethink its sector policies that they believe will lead to massive investment loss.

Will Irish Eyes Still Be Smiling When Trump Tariffs Hits Pharma?

 
• By Kevin Grogan

The US president's most recent comments suggest tariffs on pharma are imminent and Ireland has the most to lose.